Artelo Biosciences Files 8-K

TL;DR

ARTL filed an 8-K on 9/3/25, standard update, check details.

AI Summary

Artelo Biosciences, Inc. filed an 8-K on September 3, 2025, reporting other events. The company, incorporated in Nevada, is based in Solana Beach, CA, and operates in the Pharmaceutical Preparations industry. This filing does not contain specific financial transactions or material events beyond the standard reporting requirement.

Why It Matters

This 8-K filing indicates a routine update or event for Artelo Biosciences, Inc. Investors should review the details within the filing for any specific operational or strategic changes.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not disclose any immediate negative or positive material events.

Key Players & Entities

• ARTELO BIOSCIENCES, INC. (company) — Registrant
• September 3, 2025 (date) — Date of Report
• Nevada (jurisdiction) — State of Incorporation
• Solana Beach, CA (location) — Principal Executive Offices
• 2834 (industry_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ARTL The Nasdaq Stock Mar

Filing Documents

• artl_8k.htm (8-K) — 28KB
• 0001640334-25-001617.txt ( ) — 142KB
• artl-20250903.xsd (EX-101.SCH) — 5KB
• artl-20250903_lab.xml (EX-101.LAB) — 14KB
• artl-20250903_cal.xml (EX-101.CAL) — 1KB
• artl-20250903_pre.xml (EX-101.PRE) — 9KB
• artl-20250903_def.xml (EX-101.DEF) — 2KB
• artl_8k_htm.xml (XML) — 4KB

01 Other Information

Item 8.01 Other Information Announcement of Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) On September 3, 2025, Artelo Biosciences, Inc. (the "Company") announced interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial with ART27.13, the Company's peripherally acting cannabinoid receptor agonist for the treatment of cancer anorexia-cachexia syndrome (CACS). Affecting up to 80% of people living with cancer, CACS is marked by loss of appetite, weight loss, and breakdown of muscle and fat. This leading cause of death in cancer patients has no FDA-approved treatment. The Company believes the CAReS interim data comparing ART27.13 to placebo supports acceleration of the Company's partnering initiatives with its lead clinical program. The Phase 2 CAReS study is evaluating ART27.13 as a once-daily oral treatment aimed at improving weight, appetite, activity, and quality of life in cancer patients who had lost a minimum of 5% of their body weight in the prior six months. Effectiveness was measured by changes in lean body mass, weight, appetite, and activity over 12 weeks and at a 30-day follow-up. Activity and quality of life were assessed using wearable monitors and standardized questionnaires, while safety was closely tracked through adverse event reporting, laboratory tests, vital signs, visual analogue scales, and ECGs. In the interim analysis, 18 evaluable patients—primarily with lung and gastrointestinal cancers not receiving cyclic chemotherapy—were included. After 12 weeks of treatment in patients who titrated to the top dose evaluated of 1300 micrograms (n=5), ART27.13 demonstrated compelling increases in mean body weight of 6.38% (Standard Deviation or SD 9.50) compared to patients on placebo (n=6) who lost -5.42% (SD 8.17). The maximum weight gain in the ART27.13 group reached 18.5%, versus only 0.4% in placebo. The maximum weight loss in the placebo arm was -17.4%, compared to just -3.0% in

Forward Looking Statements

Forward Looking Statements This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, including future plans in respect to ART27.13, potential transactions with pharmaceutical companies or other strategic counterparties in respect of ART27.13, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this report. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARTELO BIOSCIENCES, INC. Date: September 3, 2025 /s/ Gregory D. Gorgas Gregory D. Gorgas President & Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR